ABSTRACT
Postmenopausal hormone replacement therapy (HRT) using unopposed estrogens significantly increases endometrial cancer risk and should not be used in non-hysterectomized women. Even low-potency estrogens (oral estriol) or low-dose unopposed estrogens significantly enhance the risk to develop endometrial cancer. This risk is markedly reduced, when in addition to estrogens, progestins are administered for at least 10 days (better 14 days) per month. In some studies, a normalization of endometrial cancer risk to that of women receiving no HRT was only found when a continuous combined estrogen/progestin replacement was used. The use of progestins for less than 10 days per month and long-cycle regimens, where a progestin is added only every 3 months cannot be recommended. For women needing HRT, estrogen dose should be selected as low as possible and reassessment of the need of HRT should be performed annually.
Subject(s)
Endometrial Neoplasms/etiology , Endometrial Neoplasms/prevention & control , Estrogens/adverse effects , Hormone Replacement Therapy/adverse effects , Progesterone Congeners/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Endocrine System Diseases/drug therapy , Estrogen Replacement Therapy/adverse effects , Estrogen Replacement Therapy/methods , Estrogens/therapeutic use , Female , Hormone Replacement Therapy/methods , Humans , Progesterone Congeners/therapeutic use , Risk Factors , Treatment OutcomeABSTRACT
Radical surgery in stage I and II uterine sarcoma removing all tumor manifestations is the only curative therapy option for early stage disease. Larger tumors (> 4 cm) and the presence of lymph node metastasis correlate with a high local recurrence rate. For these tumors adjuvant radiation and/or adjuvant chemotherapy may be recommended after surgical therapy. Adjuvant therapy however, should preferably be considered for uterine stromal sarcomas and mixed mesodermal tumors. The toxicity of radiation and/or chemotherapy is greater than any possible benefit for patients with leiomysarcomas as these tumors rarely respond to radiation or chemotherapy. For advanced (> stage I and II) and recurrent disease, curative therapy options are not available and palliative therapy for these patients has to take into consideration the negative side effects and weigh up quality of life against an often very limited possible benefit of such therapy.
Subject(s)
Sarcoma/diagnosis , Uterine Neoplasms/diagnosis , Female , Humans , Neoplasm Staging , Sarcoma/classification , Sarcoma/pathology , Sarcoma/therapy , Uterine Neoplasms/classification , Uterine Neoplasms/pathology , Uterine Neoplasms/therapyABSTRACT
Cervical cancer is world-wide the second most frequent cancer found in women and represents 12% of all female malignancies. In fact, it is the most common female cancer in developing countries. There is now sufficient evidence to recommend that women with locally advanced cervical cancer confined to the pelvis receive concurrent pelvic radiation and chemotherapy. New surgical techniques such as laparoscopically assisted radical vaginal hysterectomy and trachelectomy (a fertility-preserving radical operation technique) are being established and have to be evaluated for their long-term safety. Causal treatment by developing multivalent antiviral drugs and vaccines is no longer a pure theoretical approach. Despite these improvements, the early diagnosis by colposcopy and gynaecological cytology remains the safest method to ensure early treatment avoiding death of cervical cancer.
